The SARS-CoV-2 Lambda variant has been prevalent in Latin America. An analysis of the neutralization capacity of antibodies elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in plasma from healthcare workers and patients in Chile reveals that BNT162b2 elicits higher neutralizing antibody titres than CoronaVac.
- Mónica L. Acevedo
- Aracelly Gaete-Argel
- Ricardo Soto-Rifo